

Resource Summary Report

Generated by [RRID](#) on Aug 8, 2026

Phospho-Stat1 (Ser727) Antibody

RRID:AB_2197983

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9177, RRID:AB_2197983

Antibody Information

URL: http://antibodyregistry.org/AB_2197983

Proper Citation: Cell Signaling Technology Cat# 9177, RRID:AB_2197983

Target Antigen: STAT1

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IF-IC, ChIP

Antibody Name: Phospho-Stat1 (Ser727) Antibody

Description: This polyclonal targets STAT1

Target Organism: rat, mouse, human

Antibody ID: AB_2197983

Vendor: Cell Signaling Technology

Catalog Number: 9177

Record Creation Time: 20250820T025549+0000

Record Last Update: 20250820T145350+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-Stat1 (Ser727) Antibody.

No alerts have been found for Phospho-Stat1 (Ser727) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 28 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Sun L, et al. (2026) An SPP1-SOCS1 pathway constrains interferon responses in tumor-associated macrophages and shapes an immunosuppressive tumor microenvironment. *Immunity*, 59(5), 1422.

Guo W, et al. (2026) Tumor-initiating stem cells fine-tune the plasticity of neutrophils to sculpt a protective niche. *Cancer cell*, 44(1), 94.

Bizzotto M, et al. (2026) Maternal-fetal type I interferon signaling drives TREM2 dysregulation and synaptic dysfunction in neurodevelopmental disorders. *Neuron*.

Ludwig MP, et al. (2025) NF- κ B signaling directs a program of transient amplifications at innate immune response genes. *bioRxiv : the preprint server for biology*.

Zhao H, et al. (2025) Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment. *Cancer immunology research*, 13(8), 1303.

Cozzolino KA, et al. (2025) Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome. *eLife*, 13.

Walter Z, et al. (2025) An integrated proteomics approach identifies phosphorylation sites on viral and host proteins that regulate West Nile virus infection. *Cell reports*, 44(5), 115728.

Xu K, et al. (2025) Cannabinoid CB2 receptor controls chronic itch by regulating spinal microglial activation and synaptic transmission. *Cell reports*, 44(4), 115559.

Ghosh C, et al. (2024) Type I gamma phosphatidylinositol phosphate 5-kinase $\text{i}5$ controls cell sensitivity to interferon. *Developmental cell*.

Wei X, et al. (2024) Myeloid beta-arrestin 2 depletion attenuates metabolic dysfunction-associated steatohepatitis via the metabolic reprogramming of macrophages. *Cell metabolism*, 36(10), 2281.

Viengkhou B, et al. (2024) The brain microvasculature is a primary mediator of interferon- γ neurotoxicity in human cerebral interferonopathies. *Immunity*, 57(7), 1696.

Shrivastava G, et al. (2024) *Aedes aegypti* saliva modulates inflammasome activation and facilitates flavivirus infection in vitro. *iScience*, 27(1), 108620.

Wu Y, et al. (2024) Alleviation of monocyte exhaustion by BCG derivative mycolic acid. *iScience*, 27(2), 108978.

Hashimoto R, et al. (2023) MEK inhibitors increase the mortality rate in mice with LPS-induced inflammation through IL-12-NO signaling. *Cell death discovery*, 9(1), 374.

Lei Y, et al. (2023) Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity. *Cell*, 186(14), 3013.

He B, et al. (2022) Mitochondrial cristae architecture protects against mtDNA release and inflammation. *Cell reports*, 41(10), 111774.

Sooraj D, et al. (2022) MED12 and BRD4 cooperate to sustain cancer growth upon loss of mediator kinase. *Molecular cell*, 82(1), 123.

Saxton RA, et al. (2021) The tissue protective functions of interleukin-22 can be decoupled from pro-inflammatory actions through structure-based design. *Immunity*, 54(4), 660.

Liu Y, et al. (2021) Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. *Cell metabolism*, 33(6), 1221.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. *Cell systems*, 12(5), 401.